poisar

Stock

Cartesian Therapeutics, Inc. RNAC

$9.99-2.58%

Overview

RNAC market data

Price History

RNAC price chart · 1M
O
10.04
H
10.04
L
9.86
C
9.99
Vol
2,843.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$10.04
Previous Close
$10.26
Day High
$10.04
Day Low
$9.86
52 Week High
$10.88
52 Week Low
$5.78
7 Day Return
-2.68%
30 Day Return
+30.50%
90 Day Return
+32.85%
1 Year Return
+54.40%
Daily Notional Volume
$28.4K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$5.02
Diluted earnings per share over the trailing twelve months.
Beta
0.66
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-8,550.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$5.60 – $11.39
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $267.9M · P/B 2.17 · P/S 150.94.

Company News

8 captured
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price TargetBenzinga · Aug 18, 2026, 12:34 PM
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) EstimateBenzinga · Aug 6, 2026, 11:26 AM
8-K filing — Cartesian Therapeutics, Inc. (RNAC)SEC EDGAR · Aug 6, 2026, 11:03 AM
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease MarketBenzinga · Jun 9, 2026, 5:35 PM
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price TargetBenzinga · Jun 9, 2026, 5:00 PM
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price TargetBenzinga · Jun 9, 2026, 4:40 PM
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone PaymentsBenzinga · Jun 9, 2026, 11:15 AM
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightGlobenewswire Inc · Jun 2, 2026, 5:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock